Camber Capital Management’s Quest Diagnostics DGX Stock Holding History

Camber Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-600,000	Closed	-$42.9M	–	51
2016 Q1	$42.9M	Hold	600,000	–	–	2.51%	19
2015 Q4	$42.7M	Buy	600,000 +381,500	+175%	+$25.6M	2.76%	15
2015 Q3	$13.4M	Sell	218,500 -31,500	-13%	-$2.2M	1.15%	25
2015 Q2	$18.1M	Buy	+250,000	New	+$18.5M	1.23%	26
2015 Q1	–	Sell	-197,622	Closed	-$13.3M	–	38
2014 Q4	$13.3M	Sell	197,622 -302,378	-60%	-$19.1M	0.88%	31
2014 Q3	$30.3M	Sell	500,000 -600,000	-55%	-$37M	2.85%	16
2014 Q2	$64.6M	Hold	1,100,000	–	–	4.23%	4
2014 Q1	$63.7M	Buy	1,100,000 +300,000	+38%	+$16.1M	4.99%	5
2013 Q4	$42.8M	Hold	800,000	–	–	3.78%	12
2013 Q3	$49.4M	Hold	800,000	–	–	5.18%	5
2013 Q2	$48.5M	Buy	+800,000	New	+$47.7M	4.99%	5

Other funds holding DGX

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Camber Capital Management's DGX Position: Q2 2016 in Review

Camber Capital Management sold out of Quest Diagnostics (DGX) in Q2 2016, closing a stake of 600,000 shares — an estimated $42.9M sold.

Camber Capital Management first reported a position in DGX in Q2 2013 and held it in 11 quarters. The position peaked at $64.6M in Q2 2014. 558 funds tracked by Wall St. Rank hold DGX as of Q2 2016.

Camber Capital Management reported no remaining Quest Diagnostics position as of Q2 2016 after selling out during the quarter.
Camber Capital Management sold 600,000 Quest Diagnostics shares in Q2 2016, an estimated $42.9M.
Camber Capital Management first reported a position in Quest Diagnostics in Q2 2013 and held it in 11 quarters.
Camber Capital Management's Quest Diagnostics position peaked at $64.6M in Q2 2014.
558 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2016.

Based on Camber Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.